Table 1.

Baseline demographics in 134 osteomyelitis cases

	N (%)
Male	66 (49.3)
Female	68 (50.7)
Age, years, mean (range)	60 (19–97)
Age group, years
< 30	7 (5.2)
31–49	28 (20.9)
50–65	54 (40.3)
≥ 66	45 (33.6)
Weight, kg, mean (range), SD	78 (38–164), 23.8
BMI (kg/m2), mean, (range), SD	27 (15.8–48.4), 6.7
Baseline MRI	134 (100)
Infection confirmed on MRI	128 (95.5)
Baseline CRP	134 (100)
Baseline ESR	132 (98.5)
Previous antibiotic therapy	18 (13.4)
Baseline bacteremia (MRSA)	9 (6.7)
Debridement of bone or joint	121 (90.3)
Positive wound, bone, joint culture	119 (88.8)
Culture positive (wound, joint, deep wound) MRSA	92/128 with cultures obtained (71.9)
Prosthetic source	24 (17.9)
Anatomic location of infection
Lower extremity source	74 (55.2)
Upper extremity source	25 (18.7)
Pelvic source	18 (13.4)
Head and shoulder source	9 (6.7)
Vertebral source	8 (6)
Renal function at baseline
CrCl > 61 mL/min	89 (66.4)
CrCl 31–60 mL/min	12 (9)
CrCl 15– 30 mL/min	8 (6)
ESRD	7 (5.2)
Co-morbidities
≥ 3 co-morbidities	57 (42.5)
Hyperlipidemia	59 (44)
Diabetes	51 (38.1)
Peripheral vascular disease	36 (26.9)
COPD	33 (24.6)
History of MI	25 (18.7)
Congestive heart failure	25 (18.7)
Malignancy	20 (14.9)
Peptic ulcer disease	13 (9.7)
Current chemotherapy/immunotherapy	13 (9.7)
Miscellaneous
IVDU (past or present)	6 (4.5)
HIV positive	5 (3.7)
Liver disease	3 (2.2)
Chronic steroids (> 20 mg/day prednisone)	1 (0.75)
Chronic kidney insufficiency	33 (24.6)
Patient preference or transportation issues as reason for use of oritavancin	120 (89.6)

BMI body mass index, CrCl creatinine clearance, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ESRD end-stage renal disease, COPD chronic obstructive pulmonary disease, IVDU intravenous drug user, MI myocardial infarction, MRI magnetic resonance imaging, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, SD standard deviation